Home/Pipeline/DIBI (Veterinary)

DIBI (Veterinary)

Otitis Externa in Dogs

Phase 2Available for Licensing

Key Facts

Indication
Otitis Externa in Dogs
Phase
Phase 2
Status
Available for Licensing
Company

About Fe Pharmaceuticals

Fe Pharmaceuticals is a private, preclinical-stage biotech leveraging a novel platform of iron-binding polymers to treat diseases driven by iron dysregulation. Its lead candidate, DIBI, is designed to sequester iron from pathogens and rapidly dividing cells, with initial applications targeting antimicrobial-resistant infections, sepsis, and cancer. The company's approach represents a unique, non-antibiotic mechanism to address growing global threats like AMR, with a versatile pipeline spanning inhaled, IV, oral, and topical formulations.

View full company profile